Inclusion of membrane-anchored LTB or flagellin protein in H5N1 virus-like particles enhances protective responses following intramuscular and oral immunization of mice
- PMID: 30172635
- DOI: 10.1016/j.vaccine.2018.08.053
Inclusion of membrane-anchored LTB or flagellin protein in H5N1 virus-like particles enhances protective responses following intramuscular and oral immunization of mice
Abstract
We previously demonstrated that intramuscular immunization with virus-like particles (VLPs) composed of the haemagglutinin (HA), neuraminidase (NA), and matrix (M1) proteins of A/meerkat/Shanghai/SH-1/2012 (clade 2.3.2.1) protected mice from lethal challenge with viruses from other H5 HPAI clades. The inclusion of additional proteins that can serve as immunological adjuvants in VLPs may enhance adaptive immune responses following vaccination, and oral vaccines may represent the safest choice. Here, we report the generation of H5N1 VLPs composed of the viral HA, NA, and M1 proteins and membrane-anchored forms of the Escherichia coli heat-labile enterotoxin B subunit protein (LTB) or the Toll-like receptor 5 ligand flagellin (Flic). Mice intramuscularly or orally immunized with VLPs containing LTB or Flic generated greater humoural and cellular immune responses than those administered H5N1 VLPs without LTB or Flic. Intramuscular immunization with VLPs protected mice from lethal challenge with homologous or heterologous H5N1 viruses irrespective of whether the VLPs additionally included LTB or Flic. In contrast, oral immunization of mice with LTB- or Flic-VLPs conferred substantial protection against lethal challenge with both homologous and heterologous H5N1 influenza viruses, whereas mice immunized orally with VLPs lacking LTB and Flic universally succumbed to infection. Mice immunized orally with LTB- or Flic-VLPs showed 10-fold higher virus-specific IgG titres than mice immunized with H5N1-VLPs lacking LTB or Flic. Collectively, these results indicate that the inclusion of immunostimulatory proteins, such as LTB and Flic, in VLP-based vaccines may represent a promising new approach for the control of current H5N1 HPAI outbreaks by eliciting higher humoural and cellular immune responses and conferring improved cross-clade protection.
Keywords: Chimeric VLPs; H5N1 influenza; Immunogenicity; Mucosally vaccinated; Oral immunization; Vaccine.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articles
-
Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens.Virus Res. 2015 Jan 2;195:35-42. doi: 10.1016/j.virusres.2014.09.018. Virus Res. 2015. PMID: 25312452
-
Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design.Antiviral Res. 2016 Sep;133:110-8. doi: 10.1016/j.antiviral.2016.07.021. Epub 2016 Aug 1. Antiviral Res. 2016. PMID: 27491439
-
Multiple Neuraminidase Containing Influenza Virus-like Particle Vaccines Protect Mice from Avian and Human Influenza Virus Infection.Viruses. 2022 Feb 18;14(2):429. doi: 10.3390/v14020429. Viruses. 2022. PMID: 35216022 Free PMC article.
-
Virus-like particles as universal influenza vaccines.Expert Rev Vaccines. 2012 Aug;11(8):995-1007. doi: 10.1586/erv.12.70. Expert Rev Vaccines. 2012. PMID: 23002980 Free PMC article. Review.
-
Virus-like Particle Vaccines and Platforms for Vaccine Development.Viruses. 2023 May 2;15(5):1109. doi: 10.3390/v15051109. Viruses. 2023. PMID: 37243195 Free PMC article. Review.
Cited by
-
Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins.Nat Commun. 2019 Jan 21;10(1):361. doi: 10.1038/s41467-018-08265-9. Nat Commun. 2019. PMID: 30664644 Free PMC article.
-
Demystifying particle-based oral vaccines.Expert Opin Drug Deliv. 2021 Oct;18(10):1455-1472. doi: 10.1080/17425247.2021.1946511. Epub 2021 Jul 6. Expert Opin Drug Deliv. 2021. PMID: 34148474 Free PMC article. Review.
-
Immunogenicity of Recombinant Lipid-Based Nanoparticle Vaccines: Danger Signal vs. Helping Hand.Pharmaceutics. 2023 Dec 23;16(1):24. doi: 10.3390/pharmaceutics16010024. Pharmaceutics. 2023. PMID: 38258035 Free PMC article. Review.
-
Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines.BioDrugs. 2023 Mar;37(2):143-180. doi: 10.1007/s40259-022-00575-1. Epub 2023 Jan 6. BioDrugs. 2023. PMID: 36607488 Free PMC article. Review.
-
Review of the Role of Nanotechnology in Overcoming the Challenges Faced in Oral Cancer Diagnosis and Treatment.Molecules. 2023 Jul 14;28(14):5395. doi: 10.3390/molecules28145395. Molecules. 2023. PMID: 37513267 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical